Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

latest news
Venture&Growth

Gilde Healthcare company Nalu appoints Thomas West as new president and CEO

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to retire. Mr. Fender will remain as...
July 19, 2022

First Enrolment in the ProVIDE Clinical Study for BPH Treatment

test ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the commencement of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a nitinol expander designed to gently re-shape the enlarged prostate and alleviate the […]

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

test Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds a new era in digital medicine. The NICE guidance states that Sleepio, Big Health’s digital therapeutic for insomnia, is a safe […]

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding payments for an initial three programs Amphista will potentially receive up to...

Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb

Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion...

Gilde Healthcare company ADCendo appoints Dominik Mumberg, PHD, as Chief Scientific Officer

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immuno-oncology and small molecules Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Adcendo ApS (“Adcendo”), a therapeutics company focused on the development of breakthrough antibody-drug conjugates...

Gilde Healthcare anchors $103.5 million public offering by Affimed

Gilde announces that it acted as anchor investor in an upsized $103.5 million public offering by German immune-oncology company Affimed N.V. (Nasdaq: AFMD) (“Affimed”). As a result, Gilde’s ownership exceeds 5% of the outstanding share capital of Affimed. “We are excited to team up with the excellent...

Noema Pharma announces first patient dosed in phase 2b study of NOE-101 in trigeminal neuralgia

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia (TN). LibraTN is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to...

Gilde Healthcare co-leads $104 million financing in Nalu Medical

Nalu Medical, Inc. (“Nalu”), a private medtech company focused on providing minimally invasive solutions for treating chronic pain, announced today the completion of a $104 Million equity financing. The round was led by new investors Gilde Healthcare and MVM Partners. Also participating in this round were new investors Pura Vida Investments and...
Loading...
These were all messages
839e6578f5